Clinical Trials Logo

Metastatic Carcinoid Tumor clinical trials

View clinical trials related to Metastatic Carcinoid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT04993261 Recruiting - Carcinoid Tumor Clinical Trials

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Start date: September 23, 2015
Phase: Early Phase 1
Study type: Interventional

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

NCT ID: NCT02831179 Withdrawn - Clinical trials for Merkel Cell Carcinoma

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Start date: December 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually cannot be cured or controlled with treatment, has returned after a period of improvement, and cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT02399215 Completed - Carcinoid Tumor Clinical Trials

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Start date: May 15, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by slowing or stopping a certain type of receptor called vascular endothelial growth factor receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine tumors by blocking the growth of new blood vessels necessary for tumor growth.

NCT ID: NCT01841736 Active, not recruiting - Clinical trials for Metastatic Digestive System Neuroendocrine Tumor G1

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Start date: September 20, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.